-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DW+8T3JtpnSSsLTHFPrArERkFAwi2PVftcmlIIQWmXQExrQvtjFF+WRXXX5nrPR9
 oaYlGg1zRdjK3QHYYKC3Nw==

<SEC-DOCUMENT>0000950134-04-019877.txt : 20050207
<SEC-HEADER>0000950134-04-019877.hdr.sgml : 20050207
<ACCEPTANCE-DATETIME>20041223164515
ACCESSION NUMBER:		0000950134-04-019877
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041214
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20041223
DATE AS OF CHANGE:		20050207

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOTIME INC
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		041224666

	BUSINESS ADDRESS:	
		STREET 1:		935 PARDEE ST
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108459535

	MAIL ADDRESS:	
		STREET 1:		935 PARDEE STREET
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f04268e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<P align="center" style="font-size: 10pt">SECURITIES AND EXCHANGE COMMISSION

<P>
<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>


<P align="center" style="font-size: 10pt"><B>CURRENT REPORT</B>



<P align="center" style="font-size: 10pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934</B>



<P align="left" style="font-size: 10pt">Date of Report (date of earliest event reported): December&nbsp;14, 2004.


<P align="center" style="font-size: 24pt"><B>BioTime, Inc.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="75%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>California</B><BR>
(State or other jurisdiction<BR>
of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-12830</B><BR>
(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94-3127919</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>935 Pardee Street<BR>
Berkeley, California 94710</B><BR>
(Address of principal executive offices)



<P align="center" style="font-size: 10pt"><B>(510)&nbsp;845-9535</B><BR>
(Registrant&#146;s telephone number, including area code)


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:



<P align="left" style="font-size: 10pt">&#091;&nbsp;&nbsp;&nbsp;&#093; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)<BR>
&#091;&nbsp;&nbsp;&nbsp;&#093; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR>
&#091;&nbsp;&nbsp;&nbsp;&#093; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;8.01 Other Events.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">SIGNATURES</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>







<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Statements made in this Report that are not historical facts may constitute
forward-looking statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and uncertainties include but are
not limited to those discussed in this report and in BioTime&#146;s Annual Report on </I><I>Form 10-K</I><I> filed
with the Securities and Exchange Commission. Words such as &#147;expects,&#148; &#147;may,&#148; &#147;will,&#148; &#147;anticipates,&#148;
&#147;intends,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;seeks,&#148; &#147;estimates,&#148; and similar expressions identify
forward-looking statements.</I>


<P align="left" style="font-size: 10pt"><B>Section&nbsp;8-Other Events</B>


<!-- link2 "Item&nbsp;8.01 Other Events." -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events.</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;14, 2004, BioTime submitted a request to withdraw its application to the Swedish
Medical Products Agency (&#147;SMPA&#148;) for approval to market Hextend in Sweden. When BioTime filed the
application in August 2000, it hoped to obtain approval based upon its U.S. clinical trials of Hextend, which
compared Hextend to 6% hetastarch in saline solution. BioTime did not intend to do any additional
clinical studies for SMPA approval. However, the Hextend formulation includes a high molecular
weight, high degree of substitution hetastarch, and the SMPA has only approved plasma volume
expanders that contain lower molecular weight, lower degree of substitution starch. Subsequently,
the SMPA asked BioTime for clinical data comparing Hextend with a plasma volume expander containing
a lower molecular weight, lower degree of substitution starch already approved in Sweden. BioTime
has determined that conducting a large scale clinical trial would not be economical for the purpose
of obtaining regulatory approval in Sweden, and elected to request the withdrawal of its
application.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BioTime is also developing PentaLyte, a plasma volume expander that has a formulation similar
to Hextend but uses a starch that has a molecular weight and degree of substitution similar to
that of a starch used in a product approved for use in Sweden. BioTime is developing PentaLyte to
complement Hextend in its product line in order to provide physicians with a choice of products
formulated with starches having different molecular weights and degrees of substitution. However,
BioTime is first beginning its U.S. Phase II clinical trial of PentaLyte and does not yet have the
kind of clinical data that would be needed to obtain approval of PentaLyte in Sweden at this time.


<P align="center" style="font-size: 10pt">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="57%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" align="left" valign="top"><B>BIOTIME, INC.</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom" style="padding-top: 1em">
    <TD align="LEFT" nowrap valign="top">Date:&nbsp;&nbsp;&nbsp;December 23, 2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
By
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Steven Seinberg
<HR size="1" noshade>
Chief Financial Officer</TD>
</TR>

<!-- End Table Body -->
</TABLE>
</DIV>




<P align="center" style="font-size: 10pt">3
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
